Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia (AML) do
not achieve complete remission with intensive induction therapy and are therefore …

The 2016 revision of the World Health Organization classification of tumors of hematopoietic
and lymphoid tissues is characterized by a closer integration of morphology and molecular …

… Felicitas Thol MD … Felicitas Thol has received research funding from and served on
advisory boards for Novartis, Pfizer, Celgene, AbbVie, Daiichi Sankyo, Astellas, and Jazz …

Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity …

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML)
that is used for prognostic, predictive, monitoring, and efficacy-response assessments. …

Background Risk stratification and therapeutic decision-making for myelodysplastic
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), …

… (F) RFS in patients with CN-AML of the NPM1/FLT3 low-risk group according to DNMT3A …
F Damm, T Oberacker, F Thol, etal: Prognostic importance of histone methyltransferase MLL5 …

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer 1 , 2 . In patients with
myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease …

Mutations in genes of the splicing machinery have been described recently in myelodysplastic
syndromes (MDS). In the present study, we examined a cohort of 193 MDS patients for …

Purpose To study the incidence and prognostic impact of mutations in Additional sex comb-
like 1 (ASXL1) in a large cohort of patients with myelodysplastic syndrome (MDS).